ClinicalTrials.gg
CompletedNCT05508204Updated Jan 11, 2023

Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

A Phase 1 interventional study of BION-1301 in Healthy Volunteer, sponsored by Chinook Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Chinook Therapeutics, Inc. (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Phase 1, open-label study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic of multiple doses of BION-1301 in Japanese healthy subjects.

Read the detailed description

This is a Phase 1 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. This is a single-center, open-label study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic of a single subcutaneous dose of BION-1301 in Japanese healthy subjects in 3 dose level cohorts. The study will enroll up to 36 Japanese subjects across 3 dose level cohorts.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Chinook Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Chinook Therapeutics, Inc. became part of Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First generation Japanese (confirmed at screening). The definition of first generation is the subject, the subject's biological parents, and the subject's biological grandparents are of exclusively Japanese origin and were born in Japan.
  • (BMI) between 18 and 30 kg/m\^2, inclusive, at screening with a weight of at least 47 kg.
  • In good health, as determined by medical history, physical examination, vital signs assessment, 12-lead , and clinical laboratory evaluations within normal reference ranges or outside of normal reference ranges considered not by the investigator
  • Female subjects of must have a negative urine or serum pregnancy test, must agree to try to not become pregnant, must agree to consistently use highly effective methods, and must agree not to breastfeed or donate ova for a period as defined in the study protocol.
  • Male subjects must agree to use highly effective contraceptive methods and must not donate sperm for a period as defined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • History of during the last 3 years; exceptions include adequately treated basal cell carcinoma and squamous cell carcinoma of the skin
  • Confirmed systolic blood pressure >140 or \<90 mmHg, diastolic blood pressure >90 or \<50 mmHg, and pulse rate >100 or \<40 beats per minute at either screening or predose on Day 1.
  • Received a live (attenuated) vaccine(s) within 3 months prior to check-in and/or a vaccine(s) that do not contain live microorganism(s) within 14 days prior to check-in.
  • Have previously completed or withdrawn from this study or any other study investigating BION-1301, and have previously received BION-1301.
  • Positive urine drug screen, alcohol test, or cotinine test at screening or check-in.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort A

    A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level A

    Drug: BION-1301

  • Experimental
    Cohort B

    A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level B

    Drug: BION-1301

  • Experimental
    Cohort C

    A single dose of BION-1301 will be administered subcutaneously on Day 1 at dose level C

    Drug: BION-1301

Interventions

  • A solution for SC injection administered as a single dose

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of BION-1301

    Number of subjects with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs); changes from baseline in safety parameters; and number of subjects with injection site reactions

    Time frame: Day 85

Secondary outcomes

  1. Pharmacokinetics-Cmax

    Maximum plasma concentration

    Time frame: Day 85

  2. Pharmacokinetics-Tmax

    Time at which the maximum plasma concentration (Cmax) occurs

    Time frame: Day 85

  3. Pharmacokinetics-AUC∞

    Area under the plasma concentration-time curve from dosing (time zero) extrapolated to infinity

    Time frame: Day 85

  4. Pharmacokinetics-AUClast

    Area under the plasma concentration-time curve from dosing (time zero) to the time of the last measured concentration

    Time frame: Day 85

  5. Pharmacokinetics-t1/2

    Time required for the drug concentration to decrease by a factor of one-half in the terminal phase

    Time frame: Day 85

  6. Pharmacokinetics-CL/F

    Serum concentration after single dose will be measured and the apparent oral clearance will be calculated

    Time frame: Day 85

  7. Pharmacokinetics-Vz/F

    Serum concentration after single dose will be measured and the apparent volume of distribution will be calculated

    Time frame: Day 85

  8. The effect of BION-1301 on pharmacodynamic (PD) parameters

    Changes in immunoglobulin levels (IgA, IgG, and IgM)

    Time frame: Day 85

  9. The levels of anti-drug antibodies

    Blood anti-drug antibodies (ADA) and neutralizing antibody (NAb) levels

    Time frame: Day 85

07

Study locations

1 site
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 19, 2022
StartActual
Jul 19, 2022
Primary completionActual
Dec 16, 2022
CompletionActual
Dec 16, 2022
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05508204
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
Jul 19, 2022
Primary completion
Dec 16, 2022
Completion
Dec 16, 2022
Last update
Jan 11, 2023

Study contacts

Charlotte Jones-Burton, M.D.
study director · Chinook Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zigakibart

Start the discussion